Viral sexually transmitted infections: Prevention, treatments and perspectives;Infections virales sexuellement transmissibles: Prévention, traitements et perspectives

Revue Medicale Suisse

Volumn 6, Issue 246, 2010, Pages 866-870

  Nikolic, Damjan S ^a   Piguet, Vincent ^a  

^a HUG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE; VIRUS VACCINE;

ARTICLE; HERPES VIRUS INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PREVALENCE; SEXUALLY TRANSMITTED DISEASE; SKIN DEFECT; VIRUS TRANSMISSION; WART VIRUS; DISEASE TRANSMISSION;

HUMANS; SEXUALLY TRANSMITTED DISEASES, VIRAL; VIRAL VACCINES;

EID: 77952513965     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. * I. Nikolic DS, Piguet V. Vaccines and microbicides preventing HIV-1, HSV-2, and HPV mucosal transmission. J Invest Dermatol 2010;130:352-361
2. * Holmes KK, Levine R, Weaver M. Effectiveness of condoms in preventing sexually transmitted infections. Bull World Health Organ 2004;82:454-461
3. Wald A, et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA 2001;285:3100-3106 (Pubitemid 32578207)
4. Winer RL, et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med 2006;354:2645-2654 (Pubitemid 43920838)
5. Piguet V, Steinman RM. The interaction of HIV with dendritic cells: Outcomes and pathways. Trends Immunol 2007,28:503-510 (Pubitemid 350087807)
6. D'Souza G, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007;356:1944-1956 (Pubitemid 46740304)
7. Harper DM, et al. Sustained efficacy up to 4.5 years of a bivalent LI virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial. Lancet 2006;367:1247-1255
8. Paavonen J, et al. Efficacy of a prophylactic adjuvanted bivalent LI virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369:2161-2170
9. * Garland SM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-1943 (Pubitemid 46740303)
10. * FUTURE Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-1927 (Pubitemid 46740302)
11. Paavonen J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women. Lancet 2009;25;374: 301-314
12. Gilbert SC. Management and prevention of recurrent herpes labialis in immuno-competent patients. Herpes 2007;14:56-61.
13. Cirelli R, Tyring SK. Interferons in human papillomavirus infections. Antiviral Res 1994;24:191-204. (Pubitemid 24228874)
14. Schofer H. Evaluation of imiquimod for the therapy of external genital and anal warts in comparison with destructive therapies. Br J Dermatol 2007;157(Suppl. 2): 52-55 (Pubitemid 350179631)
15. Gerber S, Gremlich S. Prophylactic HPV vaccine: «A giant leap for mankind and...» questions for our society! Rev Med Suisse 2006;2:2401-2406
16. Haie-Meder C, et al. Cervical cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20(Suppl. 4):27-28
17. Meylan P. Swiss recommendations for the management of genital herpes and herpes simplex virus infection of the neonate. Rev Med Suisse 2005;1:2315-2326 (Pubitemid 44503408)
18. Grussendorf-Conen El, et al. Topical 5% imiquimod long-term treatment of cutaneous warts resistant to standard therapy modalities. Dermatology 2002;205: 139-145
19. Roberts JN. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med 2007;13:857-861
20. Corey L, et al Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: Two randomized controlled trials. Chiron HSV vaccine study group. JAMA 1999;282:331-340 (Pubitemid 29350487)
21. Stanberry LR, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002;347: 1652-1661
22. * Palliser D, et al. An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature 2006;439:89-94.
23. Van Damme L, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: A randomised controlled trial. Lancet 2002;360:971-977 (Pubitemid 35284107)
24. Cohen J. Retrovirus meeting. HIV/AIDS researchers reach for high-hanging fruit. Science 2009;323:996-997
25. Veazey RS, et al. Topically applied recombinant chemokine analogues fully protect macaques from vaginal simian-human immunodeficiency virus challenge. J Infect Dis 2009;199:1525-1527
26. Van Rompay KK, et al. Evaluation of oral tenofovir disoproxil tumarate and topical tenofovir GS-7340 to protect Infant macaques against repeated oral challenges with virulent simian immunodeficiency virus. J Acquir Immune Defic Syndr 2006;43:6-14.
27. Lederman MM, et al. Microbicides and other topical strategies to prevent vaginal transmission of HIV. Nat Rev Immunol 2006;6:371-382
28. * Pantaleo G, Koup RA. Correlates of immune protection in HIV-1 infection: What we know, what we don't know, what we should know. Nat Med 2004; 10: 806-810
29. * Rerks-Ngarm S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009;361:2209-2220